Back to top
more

Boston Scientific (BSX)

(Delayed Data from NYSE)

$87.10 USD

87.10
5,944,229

+0.90 (1.04%)

Updated Oct 11, 2024 04:00 PM ET

After-Market: $87.11 +0.01 (0.01%) 4:28 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 27% (69 out of 251)

Industry: Medical - Products

Better trading starts here.

Zacks News

Reasons to Retain QIAGEN Stock in Your Portfolio Now

Investors remain optimistic about QGEN due to its progress in test menu expansion and impressive prospects within its molecular diagnostics segments.

MCK Stock's Uptrend Likely to Continue After Core Ventures Acquisition

McKesson's agreement to acquire a controlling interest will likely bring advanced treatments and improved care experiences to patients.

HAE vs. BSX: Which Stock Is the Better Value Option?

HAE vs. BSX: Which Stock Is the Better Value Option?

Quest Diagnostics' (DGX) New Deal Aids Diagnostic Access in Ohio

Quest Diagnostics (DGX) signs an agreement to acquire select assets of University Hospitals' outreach laboratory services business.

Reasons to Retain ICON (ICLR) Stock in Your Portfolio Now

Investors remain optimistic about ICON (ICLR) due to its commitment to patient access and impressive strategic pacts.

Why Is Boston Scientific (BSX) Up 7.2% Since Last Earnings Report?

Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Abbott (ABT) Gets FDA Approval for Aspirin-Free HeartMate 3 Regimen

Abbott's (ABT) labeling update, exclusively for patients with a HeartMate 3 heart pump, secures the FDA's approval.

If You Invested $1000 in Boston Scientific a Decade Ago, This is How Much It'd Be Worth Now

Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.

Boston Scientific (BSX) is an Incredible Growth Stock: 3 Reasons Why

Boston Scientific (BSX) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Exact Sciences (EXAS) Rides on Cologuard Sales, New Launches

Exact Sciences (EXAS) identifies more than 100 opportunities with payers and health systems to address the care gaps with Cologuard through screening programs.

PROCEPT (PRCT) Grows in Urology With FDA Clearance for HYDROS

PROCEPT's (PRCT) HYDROS Robotic System leverages AI-driven technology, specifically FirstAssist AI, to optimize treatment planning.

Should You Hold Labcorp (LH) Stock in Your Portfolio Now?

Labcorp's (LH) slew of partnerships and acquisitions and robust efforts in high-growth areas bode well.

Exact Sciences (EXAS) Enrolls First Patient in Pivotal MCED Study

Exact Sciences (EXAS) initiates the MCED Falcon Registry study, with Baylor Scott & White Health and Endeavor Health serving as the primary study sites.

Reasons to Retain Bio-Rad (BIO) Stock in Your Portfolio Now

Bio-Rad's (BIO) robust digital PCR business and Clinical Diagnostics segments raise optimism. However, macro issues raise concerns.

Is Boston Scientific (BSX) Stock Outpacing Its Medical Peers This Year?

Here is how Boston Scientific (BSX) and Addex Therapeutics Ltd. Sponsored ADR (ADXN) have performed compared to their sector so far this year.

Reasons to Retain Thermo Fisher (TMO) in Your Portfolio Now

Strategic alliances and impressive product launches bode well for Thermo Fisher (TMO).

Zacks.com featured highlights ServiceNow, Boston Scientific and Cooper

ServiceNow, Boston Scientific and Cooper have been highlighted in this Screen of The Week article.

Tirthankar Chakraborty headshot

3 Profitable S&P 500 Stocks With Room to Run: NOW, BSX, COO

ServiceNow (NOW), Boston Scientific (BSX) and The Cooper Companies (COO) have been selected as the top picks with a high net income ratio.

GE HealthCare's (GEHC) Tie-Up to Boost Female Pelvic Healthcare

GE HealthCare's (GEHC) latest collaboration is likely to equip clinicians with a toolset to deliver enhanced care to female patients and improve the patient experience.

Boston Scientific (BSX), Silk Road Merger Delayed for Review

Boston Scientific (BSX) withdraws its premerger notification and report form to give the U.S. FTC more time to review the proposed acquisition of Silk Road Medical.

Alcon's (ALC) Market Share Gains, New Launches Aid Growth

Alcon (ALC) is witnessing growth in its over-the-counter portfolio, driven by favorable pricing and a sustained family of products.

Should You Hold Hologic (HOLX) Stock in Your Portfolio Now?

Hologic's (HOLX) strength in molecular diagnostics and the enriched Breast Health business are encouraging.

Walgreens (WBA) Partners With BARDA to Boost Clinical Research

Walgreens (WBA) and BARDA form a strategic partnership to bolster the decentralized clinical trial model.

Compelling Reasons to Hold Molina Healthcare (MOH) Stock Now

Molina Healthcare (MOH) remains well-poised for growth, attributable to membership growth in Medicaid and Medicare businesses. Buyouts and an adequate cash balance remain other benefits.

Urmimala Biswas headshot

Should You Buy, Sell or Hold Medtronic (MDT) Before Q1 Earnings?

Medtronic's (MDT) first-quarter profits might have been dented by higher costs and expenses originating from macro issues and geopolitical complexities. However, innovations may have boosted the top line.